AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies.

ABSTRACT: Antibody discovery is a lengthy and labor-intensive process, requiring extensive laboratory work to ensure that an antibody demonstrates the appropriate efficacy, production, and safety characteristics necessary for its use as a therapeutic agent in human patients. Traditionally, this process begins with phage display or B-cells isolation campaigns, where affinity serves as the primary selection criterion. However, the initial leads identified through this approach lack sufficient characterization in terms of developability and epitope definition, which are typically performed at late stages. In this study, we present a pipeline that integrates early-stage phage display screening with AI-based characterization, enabling more informed decision-making throughout the selection process. Using

SUBMITTER: Musnier A 

PROVIDER: S-EPMC11933058 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature